CD19 t-haNK

BIOLOGICAL3 trials

Sponsors

ImmunityBio, Inc.

Conditions

B-ALLDiffuse Large B Cell LymphomaLarge-cell LymphomaLeukemiaLymphomaLymphoma, B-CellNon-Hodgkin Lymphoma Refractory/ Relapsed

Phase 1

QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

WithdrawnNCT04052061

ImmunityBio, Inc.Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma +1

Start: 2019-09-16End: 2022-08-19Updated: 2025-02-21

Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Active, not recruitingNCT06334991

ImmunityBio, Inc.Non-Hodgkin Lymphoma Refractory/ Relapsed

Start: 2024-08-23End: 2027-10-01Updated: 2026-07-10

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

TerminatedNCT07556757

ImmunityBio, Inc.B-ALL, Leukemia

Start: 2025-04-11End: 2026-07-01Updated: 2026-08-19